Rapid Biomarker Discovery
Case Study Highlights
In this case study we share how we supported a biomarker discovery company with big data analysis, leveraging our AI and ML capabilities to generate new insights from data. Sonrai’s platform, Sonrai Discovery, has expedited the identification and validation of novel biomarkers, reducing time to discovery and saving resources.
GenoME Diagnostics is an award-winning biomarker discovery company based in Belfast, Ireland. They are developing OvaME, a cutting-edge ddPCR-based diagnostic test for ovarian cancer which has the potential to detect changes in the very earliest stages of disease. Their novel diagnostic pipeline can be utilised for biomarker in discovery in a wide range of disease and applications, such as companion diagnostics for patient selection and stratification, disease monitoring, or early diagnosis in other disease areas.
The company has now secured pre-Series A funding to develop its lead product, OvaMe, allowing the team to complete the testing phase, file for EU regulatory approval and expand its regulatory approach to the UK and North America.
GenoME Diagnostics wished to utilize industry-leading machine learning techniques to harness and unlock the full potential of their data assets. With the growing demand for AI and machine learning, companies like GenoME faced difficulties in assembling and retaining specialized data science teams. This posed a risk of missing out on invaluable insights hidden within their molecular data.
"The Sonrai Analytics team were exceptionally helpful. Initially, we did not have a great amount of experience in big data analysis, and the Sonrai team helped to walk us through the platform options and training in a way that was simple to understand, yet professional."
Dr Paul Mullan, Founder, GenoMe Diagnostics
Through a strategic partnership with Sonrai Analytics, GenoME Diagnostics seamlessly integrated machine learning into their diagnostic endeavors. By facilitating numerous machine learning experiments across diverse datasets without the need for complex coding, Sonrai Analytics has revolutionized GenoME’s biomarker discovery process.
Sonrai’s platform has expedited the identification and validation of novel biomarkers, enabling GenoME to bypass the need for extensive data science recruitment and resources. This newfound agility empowers GenoME to swiftly navigate the intricate landscape of molecular insights for diagnostic advancements.
- Assessment: Evaluate GenoMe’s data sources, identify quality issues, and potential biases.
- Harmonization: Create a framework to integrate different data types.
- Machine Learning: Design tailored ML pipelines to find diagnostic biomarkers.
- Data Security: Implement strong privacy measures and access controls.
- Training: Provide hands-on training and ongoing technical support.
- Validation: Collaborate to validate results against known biomarkers.
Saved Staff Costs
GenoME Diagnostics has achieved remarkable cost efficiency by sidestepping the need to hire additional data science staff, resulting in significant savings in operational expenses.
Reproducible Machine Learning
Over a thousand reproducible machine learning experiments have been seamlessly conducted through Sonrai’s user-friendly platform, empowering GenoME to expedite biomarker discovery.
Reduced Time to Discovery
By reducing the time required for insight generation, GenoME has elevated the quality of their diagnostic studies through enhanced data accuracy and validation.
Discover how companies worldwide grow with Sonrai. Explore all case studies.
Ready to Innovate with Data? Contact Us
We don’t talk at you. We listen and show you the stuff you’ll value most.